S&P 500
7,588.60
+0.51%
Dow Jones
52,758.90
+0.47%
Nasdaq 100
29,885.70
+0.46%
Russell 2000
2,982.51
-0.27%
FTSE 100
10,543.60
+0.61%
Nikkei 225
69,317.20
+0.42%

Investing

Amgen Fails in Bid to Expand Use of Cancer Drug (AMGN)

Photo of Paul Ausick
By Paul Ausick Published

A US drug advisory panel today denied by a 12-1 vote permission for Amgen Inc. (NASDAQ: AMGN) to market its Xgeva prostate cancer as a treatment for slowing the spread of tumors to bones in patients with advanced cases of prostate cancer. The FDA is expected to issue a final ruling on the drug in April.

If Amgen fails to gain approval for the drug, the company could lose about $1 billion in revenue in 2015, when the drug is forecast to generate $3-$4 billion in revenue for the company. Xgeva was approved in 2010 as a treatment to prevent bone pain and fractures caused by bone metastases and is also used to treat osteoporosis in menopausal women.

Amgen’s shares are down about -1.33% at $68.25 in a 52-week range of $47.66-$70.00.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Paul Ausick |

Dendreon Rises on Takeover Chatter (DNDN, LLY, AMGN)

AuthorDendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As…

Jon C. Ogg |

Dendreon Gets Prostate Cancer Competition for Provenge from Bayer’s Xofigo

via Wikimedia CommonsDendreon Corp. (NASDAQ: DNDN) has been facing problems getting its Provenge sales for advanced metastatic prostate cancer through…

Lee Jackson |

Top Biotechs Set to Win in the War on Cancer

ThinkstockTuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key…

Reality Check: Big Biotech and Big Pharma Are Becoming Identical
Jon C. Ogg |

Reality Check: Big Biotech and Big Pharma Are Becoming Identical

There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower…

Jon C. Ogg |

Opportunity Knocks: Turning Around 3 Large Biotechs (AMGN, BIIB, GENZ)

Biotech is the land of promise for emerging players.  It is also the land of stagnation for well established and…

David J. Phillips |

Dendreon Buyout, How Imminent?

Though near-term growth visibility for its cancer vaccine Provenge remains cloudy, Seattle-based Dendreon (DNDN) could be an attractive takeover candidate…

Jon C. Ogg |

Companies Betting on the Next 10 Blockbuster Drugs

24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in…

Why Amgen Is Up Despite Falling Product Sales
Chris Lange |

Why Amgen Is Up Despite Falling Product Sales

Amgen shares rose early Wednesday after it released better than expected second-quarter financial results late on Tuesday.

Why This Recently Approved Prostate Cancer Treatment Could Be Huge for Myovant
Chris Lange |

Why This Recently Approved Prostate Cancer Treatment Could Be Huge for Myovant

Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across…

Top Gaining Stocks

Meta
META • Vol: 40,760,422
CarMax
KMX • Vol: 2,288,021
Weyerhaeuser
WY • Vol: 6,523,553
SBA Communications
SBAC • Vol: 1,443,801
NVIDIA
NVDA • Vol: 148,249,982

Top Losing Stocks

Moderna
MRNA • Vol: 9,176,778
Coterra Energy
CTRA • Vol: 73,319,495
CrowdStrike
CRWD • Vol: 9,269,567
Datadog
DDOG • Vol: 5,135,556
EPAM Systems
EPAM • Vol: 1,164,561